Abstract | BACKGROUND AND PURPOSE: EXPERIMENTAL APPROACH: KEY RESULTS:
Retigabine (10 mg kg(-1) i.p., 20 mg kg(-1) p.o.) and flupirtine (20 mg kg(-1) i.p.) significantly improved dystonia, while XE-991 caused a significant aggravation in the dt sz mutant. The antidystonic effect of retigabine (10 mg kg(-1) i.p.) was counteracted by XE-991 (3 mg kg(-1) i.p.). CONCLUSIONS AND IMPLICATIONS: These data indicate that dysfunctions of neuronal Kv7 channels deserve attention in dyskinesias. Since retigabine and flupirtine are well tolerated in humans, the present finding of pronounced antidystonic efficacy in the dt sz mutant suggests that neuronal Kv7 channel activators are interesting candidates for the treatment of dystonia-associated dyskinesias and probably of other types of dystonias. The established analgesic effects of Kv7 channel openers might contribute to improvement of these disorders which are often accompanied by painful muscle spasms.
|
Authors | A Richter, S E Sander, C Rundfeldt |
Journal | British journal of pharmacology
(Br J Pharmacol)
Vol. 149
Issue 6
Pg. 747-53
(Nov 2006)
ISSN: 0007-1188 [Print] England |
PMID | 17016514
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Carbamates
- Phenylenediamines
- Potassium Channels
- ezogabine
|
Topics |
- Animals
- Carbamates
(pharmacology)
- Cricetinae
- Disease Models, Animal
- Dystonia
(prevention & control)
- Mesocricetus
- Phenylenediamines
(pharmacology)
- Potassium Channels
(drug effects)
|